Generic Mirvaso Availability
Last updated on Apr 10, 2025.
Mirvaso is a brand name of brimonidine topical, approved by the FDA in the following formulation(s):
MIRVASO (brimonidine tartrate - gel;topical)
-
Manufacturer: GALDERMA LABS LP
Approval date: August 23, 2013
Strength(s): EQ 0.33% BASE [RLD] [AB]
Is there a generic version of Mirvaso available?
A generic version of Mirvaso has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Mirvaso and have been approved by the FDA:
brimonidine tartrate gel;topical
-
Manufacturer: PADAGIS ISRAEL
Approval date: September 23, 2021
Strength(s): EQ 0.33% BASE [AB]
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Mirvaso. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Brimonidine gel compositions and methods of use
Patent 10,201,517
Issued: February 12, 2019
Inventor(s): Buge Jean-Christophe & Nadau Fourcade Karine & Meunier Cyril
Assignee(s): Galderma Laboratories, L.P.Improved topical gel compositions, such as those containing brimonidine, for the treatment of skin disorders are described. The gel compositions contain carbomer and methylparaben, and are substantially free of methylparaben crystalline particles after an extended period of storage.
Patent expiration dates:
- June 13, 2031✓
- June 13, 2031
-
Compounds, formulations, and methods for treating or preventing rosacea
Patent 7,439,241
Issued: October 21, 2008
Inventor(s): DeJovin; Jack A. et al.
Assignee(s): Galderma Laboratories, Inc. (Fort Worth, TX)In methods, compounds, and topical formulations for treatment of rosacea incorporating compounds represented by the formulas below: ##STR00001## wherein each of R.sub.1, R.sub.2, and R.sub.3 is independently hydrogen, hologen, alkyl, or alkoxy; each of R.sub.4 and R.sub.5 is independently hydrogen, alkyl, or alkoxy; and each of R.sub.6 and R.sub.7 is independently hydrogen, nitro, alkyl, or alkoxy; wherein each of A.sub.1, A.sub.3, and A.sub.4 is independently hydrogen or alkyl; and A.sub.2 is independently hydrogen or hydroxy; and wherein each of B.sub.1, B.sub.2, and B.sub.3 is independently hydrogen, hydroxy, or alkoxy; and each of B.sub.4 and B.sub.5 is independently hydrogen or alkyl, applying such compounds topically as sprays, mists, aerosols, solutions, lotions, gels, creams, ointments, pastes, unguents, emulsions, and suspensions to treat rosacea and its symptoms.
Patent expiration dates:
- August 25, 2025✓
- August 25, 2025
-
Brimonidine gel composition
Patent 8,053,427
Issued: November 8, 2011
Inventor(s): Buge; Jean-Christophe et al.
Assignee(s): Galderma R&D SNC (Biot, FR)Improved topical gel compositions, such as those containing brimonidine, for the treatment of skin disorders are described. The gel compositions contain carbomer and methylparaben, and are substantially free of methylparaben crystalline particles after an extended period of storage.
Patent expiration dates:
- June 13, 2031✓✓
- June 13, 2031
-
Gel compositions and methods of use
Patent 8,163,725
Issued: April 24, 2012
Inventor(s): Buge Jean-Christophe & Nadau-Fourcade Karine & Meunier Cyril
Assignee(s): Galderma R&D SNCImproved topical gel compositions for the treatment of skin disorders are described. The gel compositions contain carbomer and methylparaben, and are substantially free of methylparaben crystalline particles after an extended period of storage.
Patent expiration dates:
- June 13, 2031✓
- June 13, 2031
-
Compounds, formulations, and methods for ameliorating telangiectasis
Patent 8,231,885
Issued: July 31, 2012
Inventor(s): DeJovin Jack A. & DeJovin Isabelle Jean
Assignee(s): Galderma Laboratories Inc.Methods, compounds, and topical formulations for treatment of telangiectasias are disclosed. The methods comprise topically applying a composition comprising an α-adrenergic receptor agonist to telangiectatic skin. Amelioration of telangiectasia symptoms begins within minutes after topical application of a disclosed composition. A single application can significantly lessen telangiectasia discoloration for at least about 2 hours.
Patent expiration dates:
- May 24, 2025✓
- May 24, 2025
-
Methods and compositions for treating or preventing erythema
Patent 8,410,102
Issued: April 2, 2013
Inventor(s): Graeber Michael & Loesche Christian & Freidenreich Philip & Dejovin Jack A. & Dejovin Isabelle Jean & Liu Yin-Sang & Leoni Matthew James
Assignee(s): Galderma Laboratories Inc.Methods and products for treating or preventing erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical aqueous gel composition comprising about 0.01% to about 10% by weight of at least one α-adrenergic receptor agonist and a pharmaceutically acceptable carrier.
Patent expiration dates:
- May 24, 2025✓
- May 24, 2025
-
Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
Patent 8,426,410
Issued: April 23, 2013
Inventor(s): DeJovin Jack A. & DeJovin Isabelle Jean
Assignee(s): Galderma Laboratories, Inc.In methods, compounds, and topical formulations for treatment of inflammatory skin disorders incorporating compounds represented by the formulas below:
Patent expiration dates:
- May 24, 2025✓
- May 24, 2025
-
Methods and compositions for safe and effective treatment of erythema
Patent 8,513,247
Issued: August 20, 2013
Inventor(s): Graeber Michael & Loesche Christian & Freidenreich Philip & Liu Yin-Sang & Leoni Matthew J.
Assignee(s): Galderma Laboratories, L.P.Improved methods and compositions for safe and effective treatment of erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical composition comprising about 0.4% to about 0.6% by weight of brimonidine and a pharmaceutically acceptable carrier.
Patent expiration dates:
- March 25, 2031✓✓
- March 25, 2031
-
Methods and compositions for safe and effective treatment of erythema
Patent 8,513,249
Issued: August 20, 2013
Inventor(s): Graeber Michael & Loesche Christian & Freidenreich Philip & Liu Yin-Sang & Leoni Matthew J.
Assignee(s): Galderma Laboratories, L.P.Improved methods and compositions for safe and effective treatment of erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical composition comprising about 0.4% to about 0.6% by weight of brimonidine and a pharmaceutically acceptable carrier.
Patent expiration dates:
- March 25, 2031✓✓
- March 25, 2031
-
Methods and compositions for safe and effective treatment of erythema
Patent 9,861,631
Issued: January 9, 2018
Inventor(s): Graeber Michael & Loesche Christian & Freidenreich Philip & Liu Yin-sang & Leoni Matthew James
Assignee(s): Galderma Laboratories, L.P.Improved methods and compositions for safe and effective treatment of erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical composition comprising about 0.3% to about 10% by weight of brimonidine and a pharmaceutically acceptable carrier.
Patent expiration dates:
- March 25, 2031✓
- March 25, 2031
-
Methods and compositions for safe and effective treatment of erythema
Patent 9,861,632
Issued: January 9, 2018
Inventor(s): Graeber Michael & Loesche Christian & Freidenreich Philip & Liu Yin-sang & Leoni Matthew James
Assignee(s): Galderma Laboratories, L.P.Improved methods and compositions for safe and effective treatment of erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical composition comprising about 0.3% to about 10% by weight of brimonidine and a pharmaceutically acceptable carrier.
Patent expiration dates:
- March 25, 2031✓
- March 25, 2031
More about Mirvaso (brimonidine topical)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (178)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: topical anti-rosacea agents
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
AB | Products meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (e.g. identical active ingredients, dosage form, and routes of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (e.g. AB1, AB2, AB7). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.